Opendata, web and dolomites


New Reagents for Quantifying the Routing and Kinetics of T-cell Activation

Total Cost €


EC-Contrib. €






Project "KineTic" data sheet

The following table provides information about the project.


Organization address
address: RAPENBURG 70
city: LEIDEN
postcode: 2311 EZ

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 2˙000˙000 €
 EC max contribution 2˙000˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-COG
 Funding Scheme ERC-COG
 Starting year 2020
 Duration (year-month-day) from 2020-05-01   to  2025-04-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITEIT LEIDEN NL (LEIDEN) coordinator 2˙000˙000.00


 Project objective

The activation of The activation of cytotoxic T-cells (CTLs) marks the key step in the adaptive immune response against cancer and viral infections. Vaccines that activate the CTL-response against tumours are currently hotly pursued, with those targeting tumour-specific mutations now reaching the clinic. However, the capacity of these vaccines to actually activate CTLs is low and rational design improvements are needed to broaden their application. For this, better in vivo knowledge on the processes leading to CTL-activation is needed.

CTLs are activated by dendritic cells. These cells take up the vaccine, and process it to 8-10-mer peptides for presentation to CTLs on MHC-I complexes. A process called cross-presentation. In this proposal, I aim to quantify key unknowns of this pathway, relating to its kinetics and the subcellular route a vaccine takes to reach the MHC-loading site. I will:

a) Quantify the kinetics of peptide-MHC appearance, persistence and disappearance, in vivo using vaccines carrying bioorthogonal protecting/blocking groups that allow me to chemically activate, and stop, the recognition by CTLs in time. b) I will also study the sub-cellular route(s) the vaccine antigens take in vivo, by developing a second family deprotection and blocking reagents that are targeted to specific organelles.

This localised vaccine activation (or de-activation) will allow me to study the different proposed subcellular routes of the antigen in isolation and assess the importance of the many proposed subcellular routes in vivo to overall cross-presentation success.

The kinetic and routing information obtained from this new set of reagents, will allow me to shed light on some of the key unknowns relating to cross-presentation in vivo, and assess their importance to the success of CTL-activation. By using vaccine-models closely related to existing cancer vaccines, these data will in turn serve to support the rational design of better anti-tumour vaccines.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "KINETIC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "KINETIC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

SUExp (2018)

Strategic Uncertainty: An Experimental Investigation

Read More  

NanoPD_P (2020)

High throughput multiplexed trace-analyte screening for diagnostics applications

Read More  

MitoGuide (2019)

Integration and adaptation of impaired mitochondrial fitness in orchestrating T cell dysfunction in the tumor microenvironment

Read More